According to FutureWise analysis the market for Whole Genome and Exome Sequencing in 2023 is US$ 1.75 billion, and is expected to reach US$ 11.99 billion by 2031 at a CAGR of 27.20%.
The whole genome and exome sequencing market is expected to be hampered by a lack of experienced specialists and a significant reliance on funding during the forecasted period. However, ethical and legal concerns about whole exome sequencing could stymie the whole genome and exome sequencing market's growth in the near future. Whole exome sequencing (WES) is a genomic process for sequencing all of a genome's protein-coding regions. When time or resources are limited, whole genome sequencing can provide a wealth of information about single nucleotide, structural, or copy number variants, but exome sequencing is a better option.
FutureWise Market Research has instantiated a report that provides an intricate analysis of Whole Genome and Exome Sequencing Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Whole Genome and Exome Sequencing Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.